Patients with a rare and incurable blood cancer, associated with an overproduction of blood cells, will soon have access to a small molecule Novartis treatment.
A single-agent treatment for patients with relapsed or refractory myelodysplastic neoplasms has shown promising results, including overall survival, in a study.
Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals is collaborating with UK-based Exscientia to make use of an artificial intelligence-driven precision medicine platform in haematological cancers.
The organization has given 29 research grants to scientists representing 17 different US institutions pursuing lymphoma treatments and cures in their work.